

## Supporting Information

for

# **Facile synthesis of benzothiadiazine-1,1-dioxides, a precursor of RSV inhibitors, by tandem amidation/intramolecular Aza-Wittig reaction**

Krishna C. Majumdar<sup>\*,§</sup> and Sintu Ganai

Address: Department of Chemistry, University of Kalyani, Kalyani 741235, W.B India

<sup>§</sup>Tel.: +91-33-2582 8750; Fax: +91-33-2582 8282

Email: Krishna C. Majumdar - kcm@klyuniv.ac.in

\*Corresponding author

## **Experimental part**

### **General information**

Melting points were determined in open capillaries and are uncorrected. Silica gel (60–120 mesh) was used for chromatographic separation. Silica gel G was used for TLC. Petroleum ether (Pet) refers to the fraction boiling between 60 °C and 80 °C. IR spectra were recorded on a Perkin-Elmer L 120-000A spectrometer ( $\nu_{\text{max}}$  in  $\text{cm}^{-1}$ ) on KBr disks and neat.  $^1\text{H}$  NMR and  $^{13}\text{C}$  spectra were recorded in  $\text{CDCl}_3$  and DMSO (chemical shifts in  $\delta$ ) with TMS as internal standard. MS were recorded on a Q-TOF micro<sup>TM</sup> instrument at the Indian

Institute of Chemical Biology (Kolkata). CHN analyses were recorded on a Perkin-Elmer 2400 series II CHN analyzer. HRMS were recorded on a Q-TOF Micro YA263 instrument at the Indian Association for the Cultivation of Science (Kolkata).

**General procedure for the preparation of *o*-azidobenzenesulfonic acid (11) [1]:**

2-Aminobenzenesulfonic acid (11.57 g, 66.8 mmol) was dissolved in a water (45 mL) and conc. H<sub>2</sub>SO<sub>4</sub> (15 mL) mixture and cooled to 0 °C. A solution of NaNO<sub>2</sub> (6 g, 86.8 mmol) in water (30 mL) was added dropwise to it and the reaction mixture was stirred at 0 °C for 30 min. Then a cold solution of NaN<sub>3</sub> (8.68 g, 133.6 mmol) in water (30 mL) was added slowly. The reaction mixture was stirred at room temperature for a period of 12 h. The resulting precipitate was filtered off and washed with ice-cold water (10 mL) and dried under reduced pressure to give *o*-azidobenzenesulfonic acid (6.8 g, 34.1 mmol, 51%). Mp 152–154 °C (lit. 153–155 °C); IR (KBr): 1108, 1270, 1465, 1609, 2135 cm<sup>-1</sup> (lit. 2134 cm<sup>-1</sup>).

**General procedure for the preparation of 2-azido-*N*-phenylbenzenesulfonamide (10a):**

To a suspension of *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) in dichloromethane (30 mL) was added a solution of 2 M oxalyl chloride in CH<sub>2</sub>Cl<sub>2</sub> (6.280 mmol) and DMF (4 drop). The resulting mixture was heated under reflux for 3 h and then evaporated under reduced pressure. This crude *o*-azidobenzenesulfonyl chloride was added in small portions to a vigorously stirred mixture of the corresponding amine (here aniline 350 mg, 3.765 mmol) and NaOAc (310 mg, 3.765 mmol) in 50% aq MeOH (15 mL) over a period of 30 min. The mixture was then stirred at 60 °C for 1 h, cooled to room temperature, diluted with water (30 mL) and acidified to pH 2 with conc. HCl. The precipitate was filtered off, washed thoroughly with water and recrystallized from EtOAc to afford the grey solid product **10a** (571 mg, 2.084 mmol, 83%) [Found: C, 52.71; H, 3.86; N, 20.18 %. C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub>S requires C, 52.54; H, 3.67; N, 20.43 %] *R*<sub>f</sub> (15% EtOAc/Pet) 0.48; Mp 255–257 °C; IR (KBr): 1155, 1472, 2130, 3254 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ<sub>H</sub> 7.05–7.12 (m, 4H, ArH), 7.16–7.24 (m, 3H, ArH), 7.28 (s, 1H, NH), 7.53 (t, *J* = 8.0 Hz, 1H, ArH), 7.90 (d, *J* = 8.0 Hz, 1H, ArH); <sup>13</sup>C NMR

(100 MHz, CDCl<sub>3</sub>)  $\delta_C$  119.4, 121.2, 124.8, 125.5, 128.9, 129.3, 131.3, 134.4, 136.1, 137.7; HRMS-ESI  $m/z$  found 275.0610 (MH<sup>+</sup>), C<sub>13</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub>S requires 275.0607 (MH<sup>+</sup>).

**Characterization of ethyl 2-azidophenylsulfonyl-(4-chlorophenyl)-carbamate (9b):**

White gummy liquid;  $R_f$  (15% EtOAc/Pet) 0.58; IR (neat): 1158, 1332, 1510, 1711, 2134 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta_H$  1.08 (t,  $J$  = 7.2 Hz, 3H, COOCH<sub>2</sub>CH<sub>3</sub>), 4.09 (q,  $J$  = 7.2 Hz, 2H, COOCH<sub>2</sub>CH<sub>3</sub>), 7.32-7.36 (m, 2H, ArH), 7.40-7.46 (m, 4H, ArH), 7.68 (td,  $J$  = 6.4, 1.6 Hz, 1H, ArH), 8.22 (dd,  $J$  = 8.0, 1.6 Hz, 1H, ArH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta_C$  13.9, 63.8, 119.8, 124.6, 129.3, 129.4, 131.5, 133.4, 133.5, 135.2, 135.4, 138.5, 151.9.

**2-azido-*N*-(4-chlorophenyl)benzenesulfonamide (10b):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and *p*-chloroaniline (480 mg, 3.765 mmol), compound **10b** was isolated as a gummy liquid (627 mg, 2.035 mmol, 81%);  $R_f$  (15% EtOAc/Pet) 0.51; IR (neat): 1160, 1331, 2136, 3251 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta_H$  7.04-7.07 (m, 3H, ArH), 7.17-7.19 (m, 2H, ArH), 7.22 (s, 1H, NH), 7.27 (d,  $J$  = 8.0 Hz, 1H, ArH), 7.56 (t,  $J$  = 7.6 Hz, 1H, ArH), 7.88 (d,  $J$  = 8.0 Hz, 1H, ArH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta_C$  118.5, 121.8, 124.8, 125.4, 129.0, 129.1, 129.5, 132.5, 133.0, 136.5, 136.9; HRMS-ESI  $m/z$  found 331.0042 (MNa<sup>+</sup>), C<sub>12</sub>H<sub>9</sub>ClN<sub>4</sub>O<sub>2</sub>SNa requires 331.0032 (MNa<sup>+</sup>).

**Characterization of iminophosphorane intermediate (12b):**

White solid;  $R_f$  (15% EtOAc/Pet) 0.45; Mp 128–130 °C; IR (KBr): 1158, 1332, 1548, 1711 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta_H$  1.12 (t,  $J$  = 6.8 Hz, 3H, COOCH<sub>2</sub>CH<sub>3</sub>), 4.03-4.15 (m, 2H, COOCH<sub>2</sub>CH<sub>3</sub>), 6.41 (d,  $J$  = 8.0 Hz, 1H, ArH), 6.66 (t,  $J$  = 7.6 Hz, 1H, ArH), 6.70-6.78 (m, 1H, ArH), 6.81 (d,  $J$  = 8.4 Hz, 1H, ArH), 6.99 (t,  $J$  = 7.6 Hz, 1H, ArH), 7.14 (d,  $J$  = 8.0 Hz, 1H, ArH), 7.33-7.38 (m, 7H, ArH), 7.47-7.54 (m, 3H, ArH), 7.63-7.68 (m, 5H, ArH), 7.72 (d,  $J$  = 8.0 Hz, 1H, ArH), 8.08 (d,  $J$  = 7.6 Hz, 1H, ArH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta_C$  14.0, 63.7, 115.4, 116.9, 117.7, 119.4, 122.8, 122.9, 128.1, 128.7, 128.8, 129.0, 129.4, 130.0,

131.4, 131.7, 132.0, 132.1, 132.7, 132.8, 133.8, 134.1, 134.5, 134.9, 135.3, 135.4, 146.9, 151.7, 152.3, 152.5.

**Characterization of ethyl 2-aminophenylsulfonyl-(4-chlorophenyl)-carbamate (14b):**

White solid;  $R_f$  (15% EtOAc/Pet) 0.55; Mp 113–115 °C; IR (KBr): 1161, 1336, 1561, 1719, 3382, 3390  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.13 (t,  $J = 7.2$  Hz, 3H,  $\text{COOCH}_2\text{CH}_3$ ), 4.13 (q,  $J = 7.2$  Hz, 2H,  $\text{COOCH}_2\text{CH}_3$ ), 5.08 (m, 2H,  $\text{NH}_2$ ), 6.72–6.79 (m, 2H, ArH), 7.28 (d,  $J = 8.8$  Hz, 2H, ArH), 7.33–7.37 (m, 1H, ArH), 7.40 (d,  $J = 8.8$  Hz, 2H, ArH), 7.72 (d,  $J = 8.0$  Hz, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  13.8, 63.7, 119.7, 124.4, 128.9, 129.3, 131.5, 133.4, 133.5, 135.2, 135.4, 138.3, 151.4.

***N*-(4-acetylphenyl)-2-azidobenzenesulfonamide (10c):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and 1-(4-aminophenyl)ethanone (508 mg, 3.765 mmol), compound **10c** was isolated as a grey solid (690 mg, 2.183 mmol, 87%); [Found: C, 53.09; H, 3.88; N, 17.92;  $\text{C}_{14}\text{H}_{12}\text{N}_4\text{O}_3\text{S}$  requires C, 53.16; H, 3.82; N, 17.71]  $R_f$  (15% EtOAc/Pet) 0.46; Mp decomposed at 200 °C; IR (KBr): 1160, 1339, 1669, 2102, 3208  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  2.51 (s, 3H,  $\text{COCH}_3$ ), 7.19 (t,  $J = 8.2$  Hz, 2H, ArH), 7.25–7.27 (m, 2H, ArH), 7.33 (s, 1H, NH), 7.58 (t,  $J = 7.8$  Hz, 1H, ArH), 7.82 (d,  $J = 8.4$  Hz, 2H, ArH), 7.99 (d,  $J = 7.6$  Hz, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  26.4, 119.1, 119.6, 124.9, 129.9, 131.4, 133.6, 134.8, 137.8, 140.7, 196.6.

**Methyl 4-(2-azidophenylsulfonamido)benzoate (10d):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and methyl 4-aminobenzoate (569 mg, 3.765 mmol), compound **10d** was isolated as a grey solid (700 mg, 2.108 mmol, 84%); [Found: C, 50.71; H, 3.57; N, 16.93;  $\text{C}_{14}\text{H}_{12}\text{N}_4\text{O}_4\text{S}$  requires C, 50.60; H, 3.64; N, 16.86]  $R_f$  (30% EtOAc/Pet) 0.47; Mp 188–190 °C; IR (KBr): 1165, 1345, 1695, 2106, 3212  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO)  $\delta_{\text{H}}$  3.75 (s, 3H,  $\text{COOCH}_3$ ), 7.20 (d,  $J = 8.2$  Hz, 2H, ArH), 7.31 (m, 1H, ArH), 7.49 (m, 1H, ArH), 7.64 (d,  $J =$

7.6 Hz, 1H, ArH), 7.78 (d,  $J$  = 8.2 Hz, 2H, ArH), 7.95 (d,  $J$  = 7.0 Hz, 1H, ArH), 10.90 (s, 1H, NH);  $^{13}\text{C}$  NMR (100 MHz, DMSO)  $\delta_{\text{C}}$  52.0, 117.9, 121.3, 124.3, 125.0, 128.6, 130.6, 130.8, 135.0, 137.7, 142.1, 165.7.

#### **2-azido-*N*-*p*-tolylbenzenesulfonamide (10e):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and *p*-methylaniline (403 mg, 3.765 mmol), compound **10e** was isolated as a white solid (636 mg, 2.208 mmol, 88%); [Found: C, 53.91; H, 4.12; N, 19.61 %.  $\text{C}_{13}\text{H}_{12}\text{N}_4\text{O}_2\text{S}$  requires C, 54.15; H, 4.20; N, 19.43 %]  $R_{\text{f}}$  (15% EtOAc/Pet) 0.47; Mp 138–140 °C; IR (KBr): 1159, 1331, 2134, 3263  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  2.23 (s, 3H,  $\text{CH}_3$ ), 6.98–7.02 (m, 5H, NH and ArH overlapped), 7.14 (dt,  $J$  = 8.4, 0.8 Hz, 1H, ArH), 7.26 (d,  $J$  = 8.8 Hz, 1H, ArH), 7.52 (dt,  $J$  = 8.4, 1.6 Hz, 1H, ArH), 7.86 (dd,  $J$  = 8.0, 1.2 Hz, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  20.8, 119.4, 121.9, 124.8, 129.0, 129.9, 131.3, 133.4, 134.3, 135.6, 137.6.

#### **2-azido-*N*-(4-methoxyphenyl)benzenesulfonamide (10f):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and *p*-methoxyaniline (463 mg, 3.765 mmol), compound **10f** was isolated as a grey solid (649 mg, 2.134 mmol, 85%); [Found: C, 51.03; H, 4.10; N, 18.57 %.  $\text{C}_{13}\text{H}_{12}\text{N}_4\text{O}_3\text{S}$  requires C, 51.31; H, 3.97; N, 18.41 %]  $R_{\text{f}}$  (15% EtOAc/Pet) 0.48; Mp 116–118 °C; IR (KBr): 1163, 1311, 2139, 3277  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  3.72 (s, 3H,  $\text{OCH}_3$ ), 6.72 (dd,  $J$  = 6.8, 2.0 Hz, 2H, ArH), 6.87 (s, 1H, NH), 7.01 (dd,  $J$  = 7.6, 2.0 Hz, 2H, ArH), 7.14 (t,  $J$  = 7.6 Hz, 1H, ArH), 7.29 (d,  $J$  = 8.0 Hz, 1H, ArH), 7.54 (dt,  $J$  = 8.0, 1.6 Hz, 1H, ArH), 7.80 (dd,  $J$  = 8.0, 1.6 Hz, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  55.4, 114.5, 119.3, 124.7, 124.8, 124.9, 128.6, 129.0, 131.3, 134.2, 137.6.

#### **2-azido-*N*-benzylbenzenesulfonamide (10g):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and benzylamine (403 mg, 3.675 mmol), compound **10g** was isolated as a light

tan solid (579 mg, 2.010 mmol, 80%); [Found: C, 53.81; H, 4.06; N, 19.65 %.  $C_{13}H_{12}N_4O_2S$  requires C, 54.15; H, 4.20; N, 19.43 %]  $R_f$  (15% EtOAc/Pet) 0.50; Mp 80–82 °C; IR (KBr): 1165, 1327, 2142, 3292  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta_H$  4.10 (d,  $J$  = 6.0 Hz, 2H,  $NCH_2$ ), 5.28 (brs, 1H, NH), 7.16–7.23 (m, 7H, ArH), 7.55 (t,  $J$  = 7.2 Hz, 1H, ArH), 7.98 (d,  $J$  = 7.6 Hz, 1H, ArH);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ )  $\delta_C$  47.6, 119.3, 124.8, 127.9, 128.0, 128.4, 128.5, 130.0, 130.6, 134.0, 136.0, 137.5.

#### **2-azido-*N*-methylbenzenesulfonamide (10h):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and methylamine solution (10 mL), compound **10h** was isolated as a colourless solid (442 mg, 2.084 mmol, 83%); [Found: C, 39.86; H, 4.05; N, 26.17 %.  $C_7H_8N_4O_2S$  requires C, 39.62; H, 3.80; N, 26.40 %]  $R_f$  (15% EtOAc/Pet) 0.53; Mp 136–138 °C; IR (KBr): 1161, 1326, 2142, 3305  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta_H$  2.61 (d,  $J$  = 5.2 Hz, 3H,  $CH_3$ ), 4.94 (d,  $J$  = 4.8 Hz, 1H, NH), 7.27 (d,  $J$  = 8.0 Hz, 1H, ArH), 7.31 (d,  $J$  = 8.4 Hz, 1H, ArH), 7.60 (dt,  $J$  = 8.8, 0.8 Hz, 1H, ArH), 7.99 (d,  $J$  = 7.6 Hz, 1H, ArH);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ )  $\delta_C$  29.4, 119.4, 124.9, 128.4, 131.1, 134.1, 137.6.

#### **2-azido-*N*-(2-oxo-2*H*-chromen-6-yl)benzenesulfonamide (10i):**

Using the general procedure (as **10a**) starting from *o*-azidobenzenesulfonic acid (500 mg, 2.510 mmol) and 6-aminocoumarin (605 mg, 3.765 mmol), compound **10i** was isolated as a brown solid (773 mg, 2.260 mmol, 90%); [Found: C, 52.78; H, 3.15; N, 16.11%.  $C_{15}H_{10}N_4O_4S$  requires C, 52.63; H, 2.94; N, 16.37%.]  $R_f$  (30% EtOAc/Pet) 0.50; Mp 194–196 °C decomposed; IR (KBr): 1160, 1310, 2128, 1711, 3282  $cm^{-1}$ ;  $^1H$  NMR (400 MHz, DMSO)  $\delta_H$  6.43 (d,  $J$  = 9.6 Hz, 1H, =CH of coumarin), 7.26–7.35 (m, 3H, ArH), 7.43 (d,  $J$  = 2.4 Hz, 1H, ArH), 7.52 (d,  $J$  = 8.0 Hz, 1H, ArH), 7.64 (t,  $J$  = 7.6 Hz, 1H, ArH), 7.84 (d,  $J$  = 8.0 Hz, 1H, ArH), 8.00 (d,  $J$  = 9.6 Hz, 1H, =CH of coumarin), 10.48 (s, 1H, NH);  $^{13}C$  NMR (100 MHz,  $CDCl_3$  + DMSO)  $\delta_C$  116.9, 117.3, 118.7, 119.0, 119.8, 124.4, 124.6, 129.0, 131.0, 133.8, 134.3, 137.8, 143.2, 150.6, 160.4.

**General procedure for the preparation of 2-*N*-phenyl-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13a):**

2-azido-*N*-phenylbenzenesulfonamide (150 mg, 0.547 mmol) and Et<sub>3</sub>N (1.094 mmol) in 5 mL xylene was taken in a sealed tube and ethyl carbonochloridate (89 mg, 0.820 mmol) was added dropwise and stirred at room temperature for 30 minutes. Then Ph<sub>3</sub>P (215 mg, 0.820 mmol) was added to it and it was sealed with the cap tightly and the reaction was heated at 135 °C. After completion of the reaction as monitored by TLC, the reaction mixture was cooled, water (20 mL) was added, and the mixture was extracted with ethyl acetate (3 × 30 mL). The ethyl acetate extract was washed with water (2 × 40 mL), followed by brine (30 mL). The organic layer was dried (over Na<sub>2</sub>SO<sub>4</sub>), and the solvent was evaporated to give a crude product. This was purified by column chromatography over silica gel (230–400 mesh) using petroleum ether and ethyl acetate (4:1) as an eluent. The product **13a** was isolated as a white solid (149 mg, 0.493 mmol, 90%); *R*<sub>f</sub> (20% EtOAc/Pet) 0.47; Mp 116–118 °C; IR (KBr): 1155, 1306, 1338, 1579, 1610 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ<sub>H</sub> 1.26 (t, *J* = 6.9 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>), 4.45 (q, *J* = 6.9 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 7.33–7.56 (m, 7H, ArH), 7.66 (td, *J* = 7.5, 3.0 Hz, 1H, ArH), 7.89 (d, *J* = 7.2 Hz, 1H, ArH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ<sub>C</sub> 14.0, 65.1, 122.0, 124.7, 126.1, 126.7, 129.3, 129.6, 129.8, 131.4, 133.8, 141.8, 150.7; HRMS-ESI *m/z* found 303.0801 (MH<sup>+</sup>), C<sub>15</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub>S requires 303.0803 (MH<sup>+</sup>).

**2-*N*-(4-chlorophenyl)-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13b):**

Using the general procedure (as **13a**) starting from 2-azido-*N*-(4-chlorophenyl)benzenesulfonamide (150 mg, 0.487 mmol), compound **13b** was isolated as a white solid (154 mg, 0.458 mmol, 94%); *R*<sub>f</sub> (20% EtOAc/Pet) 0.55; Mp 102–104 °C; IR (KBr): 1186, 1310, 1338, 1577, 1610 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ<sub>H</sub> 1.25 (t, *J* = 7.2 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>), 4.43 (q, *J* = 6.9 Hz, 2, OCH<sub>2</sub>CH<sub>3</sub>), 7.34–7.38 (m, 3H, ArH), 7.44 (d, *J* = 8.4 Hz, 3H, ArH), 7.65 (t, *J* = 7.8 Hz, 1H, ArH), 7.86 (d, *J* = 8.0 Hz, 1H, ArH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ<sub>C</sub> 14.0, 65.3, 122.0, 124.9, 125.9, 126.8, 129.6, 129.8, 131.1, 134.0, 135.8, 141.7,

150.3; HRMS-ESI  $m/z$  found 337.0409 ( $MH^+$ ), 339.0380 ( $MH^++2$ ),  $C_{15}H_{14}ClN_2O_3S$  requires 337.0414 ( $MH^+$ ), 339.0384 ( $MH^++2$ ).

**2-*N*-(4-acetylphenyl)-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13c):**

Using the general procedure (as **13a**) starting from *N*-(4-acetylphenyl)-2-azidobenzenesulfonamide (150 mg, 0.474 mmol), compound **13c** was isolated as a white solid (150 mg, 0.436 mmol, 92%);  $R_f$  (20% EtOAc/Pet) 0.48; Mp 143–145 °C; IR (KBr): 1159, 1311, 1585, 1615, 1682  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta_H$  1.25 (t,  $J$  = 6.8 Hz, 3H,  $OCH_2CH_3$ ), 2.65 (s, 3H,  $COCH_3$ ), 4.45 (q,  $J$  = 6.8 Hz, 2H,  $OCH_2CH_3$ ), 7.36 (t,  $J$  = 7.6 Hz, 1H, ArH), 7.46–7.51 (m, 3H, ArH), 7.66 (t,  $J$  = 7.8 Hz, 1H, ArH); 7.86 (d,  $J$  = 8.0 Hz, 1H, ArH), 8.05 (d,  $J$  = 8.4 Hz, 2H, ArH);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ )  $\delta_C$  12.0, 26.7, 65.4, 122.0, 125.0, 126.0, 126.9, 129.3, 129.7, 134.0, 135.8, 137.7, 141.7, 151.1, 197.0; HRMS-ESI  $m/z$  found 345.0903 ( $MH^+$ ),  $C_{17}H_{17}N_2O_4S$  requires 345.0909 ( $MH^+$ ).

**2-*N*-(*p*-methoxycarbonylphenyl)-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13d):**

Using the general procedure (as **13a**) starting from methyl 4-(2-azidophenylsulfonamido)benzoate (150 mg, 0.451 mmol), compound **13d** was isolated as a white solid (154 mg, 0.429 mmol, 95%);  $R_f$  (20% EtOAc/Pet) 0.45; Mp 160–162 °C; IR (KBr): 1179, 1312, 1583, 1619, 1718  $cm^{-1}$ ;  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta_H$  1.24 (t,  $J$  = 7.2 Hz, 3H,  $OCH_2CH_3$ ), 3.95 (s, 3H,  $COOCH_3$ ), 4.44 (q,  $J$  = 7.2 Hz, 2H,  $OCH_2CH_3$ ), 7.36 (td,  $J$  = 7.6, 0.8 Hz, 1H, ArH), 7.45–7.48 (m, 3H, ArH), 7.65 (td,  $J$  = 8.4, 1.4 Hz, 1H, ArH), 7.86 (dd,  $J$  = 8.0, 1.2 Hz, 1H, ArH), 8.14 (dd,  $J$  = 8.4, 1.6 Hz, 2H, ArH);  $^{13}C$  NMR (100 MHz,  $CDCl_3$ )  $\delta_C$  14.0, 52.4, 65.3, 122.0, 125.0, 126.1, 126.9, 129.6, 130.6, 131.2, 134.0, 135.7, 141.7, 150.2, 166.1; HRMS-ESI  $m/z$  found 361.0849 ( $MH^+$ ),  $C_{17}H_{17}N_2O_5S$  requires 361.0858 ( $MH^+$ ).

**2-*N*-*p*-tolyl-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13e):**

Using the general procedure (as **13a**) starting from 2-azido-*N*-*p*-tolylbenzenesulfonamide (150 mg, 0.520 mmol), compound **13e** was isolated as a white solid (132 mg, 0.417 mmol, 80%);  $R_f$  (20% EtOAc/Pet) 0.53; Mp 108–110 °C; IR (KBr): 1156, 1305, 1340, 1580,



1611  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.25 (t,  $J = 7.2$  Hz, 3H,  $\text{OCH}_2\text{CH}_3$ ), 2.41 (s, 3H,  $p$ - $\text{ArCH}_3$ ), 4.43 (q,  $J = 7.2$  Hz, 2H,  $\text{OCH}_2\text{CH}_3$ ), 7.25-7.32 (m, 4H, ArH), 7.33 (t,  $J = 7.6$  Hz, 1H, ArH), 7.44 (d,  $J = 8.0$  Hz, 1H, ArH), 7.62 (t,  $J = 7.6$  Hz, 1H, ArH), 7.86 (d,  $J = 7.6$  Hz, 1H, ArH);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  14.1, 21.3, 65.1, 122.0, 124.7, 126.1, 126.7, 128.6, 129.6, 130.1, 133.8, 139.9, 142.0, 150.9; HRMS-ESI  $m/z$  found 317.0965 ( $\text{MH}^+$ ),  $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_3\text{S}$  requires 317.0960 ( $\text{MH}^+$ ).

### **2-*N*-(4-methoxyphenyl)-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13f):**

Using the general procedure (as **13a**) starting from 2-azido-*N*-(4-methoxyphenyl)benzenesulfonamide (150 mg, 0.493 mmol), compound **13f** was isolated as a white solid (136 mg, 0.409 mmol, 83%);  $R_f$  (20% EtOAc/Pet) 0.50; Mp 148–150  $^{\circ}\text{C}$ ; IR (KBr): 1167, 1334, 1581, 1611  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.27 (t,  $J = 6.9$  Hz, 3H,  $\text{OCH}_2\text{CH}_3$ ), 3.87 (s, 3H,  $\text{OCH}_3$ ), 4.44 (q,  $J = 6.9$  Hz, 2H,  $\text{OCH}_2\text{CH}_3$ ), 6.98 (d,  $J = 8.7$  Hz, 2H, ArH), 7.28-7.37 (m, 3H, ArH), 7.45 (d,  $J = 7.8$  Hz, 1H, ArH), 7.63 (td,  $J = 8.4, 1.5$  Hz, 1H, ArH), 7.88 (d,  $J = 7.8$  Hz, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  14.0, 55.5, 65.0, 114.6, 122.1, 123.4, 124.6, 126.0, 126.7, 131.1, 133.8, 141.8, 150.9, 160.5; HRMS-ESI  $m/z$  found 333.0911 ( $\text{MH}^+$ ),  $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_4\text{S}$  requires 333.0909 ( $\text{MH}^+$ ).

### **2-*N*-benzyl-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13g):**

Using the general procedure (as **13a**) starting from 2-azido-*N*-benzylbenzenesulfonamide (150 mg, 0.520 mmol), compound **13g** was isolated as a white solid (143 mg, 0.452 mmol, 87%);  $R_f$  (20% EtOAc/Pet) 0.54; Mp 85–87  $^{\circ}\text{C}$ ; IR (KBr): 1152, 1327, 1584, 1613  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.28 (t,  $J = 7.2$  Hz, 3H,  $\text{OCH}_2\text{CH}_3$ ), 4.40 (q,  $J = 7.2$  Hz, 2H,  $\text{OCH}_2\text{CH}_3$ ), 5.04 (s, 2H,  $\text{NCH}_2\text{Ph}$ ), 7.25-7.36 (m, 7H, ArH), 7.57 (td,  $J = 8.0, 1.2$  Hz, 1H, ArH), 7.86 (d,  $J = 8.0$  Hz, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  14.0, 45.2, 65.1, 121.7, 124.6, 125.5, 126.6, 127.9, 128.3, 128.5, 133.7, 135.9, 141.7, 150.9; HRMS-ESI  $m/z$  found 317.0967 ( $\text{MH}^+$ ),  $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_3\text{S}$  requires 317.0960 ( $\text{MH}^+$ ).

**2-*N*-methyl-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13h):**

Using the general procedure (as **13a**) starting from 2-azido-*N*-methylbenzenesulfonamide (150 mg, 0.707 mmol), compound **13h** was isolated as a white solid (134 mg, 0.558 mmol, 79%);  $R_f$  (20% EtOAc/Pet) 0.45; Mp 136–138 °C; IR (KBr): 1156, 1305, 1340, 1580, 1611  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.42 (t,  $J = 7.2$  Hz, 3H,  $\text{OCH}_2\text{CH}_3$ ), 3.38 (s, 3H,  $\text{NCH}_3$ ), 4.49 (q,  $J = 7.2$  Hz, 2H,  $\text{OCH}_2\text{CH}_3$ ), 7.28 (t,  $J = 7.8$  Hz, 1H, ArH), 7.35 (d,  $J = 8.0$  Hz, 1H, ArH), 7.58 (td,  $J = 7.8, 1.2$  Hz, 1H, ArH), 7.82 (d,  $J = 8.0$  Hz, 1H, ArH);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  14.2, 27.1, 65.0, 121.6, 124.4, 124.7, 126.4, 133.7, 141.8, 151.3; HRMS-ESI  $m/z$  found 241.0639 ( $\text{MH}^+$ ),  $\text{C}_{10}\text{H}_{13}\text{N}_2\text{O}_3\text{S}$  requires 241.0647 ( $\text{MH}^+$ ).

**2-*N*-(2-oxo-2*H*-chromen-6-yl)-3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (13i):**

Using the general procedure (as **13a**) starting from 2-azido-*N*-(2-oxo-2*H*-chromen-6-yl)benzenesulfonamide (150 mg, 0.438 mmol), compound **13i** was isolated as a white solid (144 mg, 0.390 mmol, 89%);  $R_f$  (25% EtOAc/Pet) 0.40; Mp 193–195 °C; IR (KBr): 1186, 1339, 1592, 1629, 1733  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{H}}$  1.27 (t,  $J = 6.9$  Hz, 3H,  $\text{OCH}_2\text{CH}_3$ ), 4.46 (q,  $J = 6.9$  Hz, 2H,  $\text{OCH}_2\text{CH}_3$ ), 6.51 (d,  $J = 9.6$  Hz, 1H, =CH of coumarin), 7.35–7.55 (m, 4 H, ArH), 7.63–7.68 (m, 2H, ArH), 7.73 (d,  $J = 9.6$  Hz, 1H, =CH of coumarin), 7.88 (d,  $J = 8.1$  Hz, 1H, ArH);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ )  $\delta_{\text{C}}$  14.1, 65.5, 117.7, 118.1, 119.4, 122.1, 125.0, 125.8, 127.0, 127.3, 129.3, 133.2, 134.2, 141.6, 142.7, 154.5, 160.0; HRMS-ESI  $m/z$  found 371.0710 ( $\text{MH}^+$ ),  $\text{C}_{18}\text{H}_{15}\text{N}_2\text{O}_5\text{S}$  requires 371.0702 ( $\text{MH}^+$ ).

**General procedure for the preparation of 2-*N*-substituted-1,2,4-benzothiadiazine-3-one 1,1-dioxide derivatives (15):**

50 mg 3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide (**13**) was taken in a round bottomed flask in ethanol (4 mL) and HCl (1 mL) was added to it. The reaction mixture was heated at 80 °C for 4 h. After completion of the reaction as monitored by TLC the solvent was evaporated and saturated  $\text{NaHCO}_3$  solution (10 mL) was added to it and extracted with ethyl acetate (3 × 10 mL). The ethyl acetate extract was washed with water (2 × 15 mL), followed by brine

(10 mL). The organic layer was dried (over Na<sub>2</sub>SO<sub>4</sub>), and the solvent was evaporated and passed through a short column to yield solid product **15**.

**2-*N*-(4-acetylphenyl)-1,2,4-benzothiadiazine-3-one 1,1-dioxide (15c):**

Using the general procedure starting from compound **13c** (50 mg, 0.145 mmol), compound **15c** was isolated as a white solid (43 mg, 0.136 mmol, 94%); *R*<sub>f</sub> (30% EtOAc/Pet) 0.42; Mp 123–125 °C; IR (KBr): 1181, 1340, 1608, 1686, 1698, 3076 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub> + DMSO) δ<sub>H</sub> 2.49 (s, 3 H, COCH<sub>3</sub>), 7.25–7.34 (m, 2H, ArH), 7.58–7.62 (m, 3H, ArH), 7.84 (d, *J* = 7.6 Hz, 1H, ArH), 8.08 (d, *J* = 8.0 Hz, 2H, ArH), 11.19 (s, 1H, NH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub> + DMSO) δ<sub>C</sub> 26.8, 117.7, 122.7, 123.0, 123.3, 129.4, 130.8, 134.6, 134.8, 135.1, 137.8, 150.1, 197.1; HRMS-ESI *m/z* found 317.0591 (MH<sup>+</sup>), C<sub>15</sub>H<sub>13</sub>N<sub>2</sub>O<sub>4</sub>S requires 317.0596 (MH<sup>+</sup>).

**2-*N*-*p*-tolyl-1,2,4-benzothiadiazine-3-one 1,1-dioxide (15e):**

Using the general procedure starting from compound **13e** (50 mg, 0.158 mmol), compound **15e** was isolated as a white solid (44 mg, 0.152 mmol, 96%); *R*<sub>f</sub> (30% EtOAc/Pet) 0.47; Mp 250–252 °C; IR (KBr): 1187, 1345, 1360, 1602, 1708, 3089 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ<sub>H</sub> 2.43 (s, 3H, *p*-ArCH<sub>3</sub>), 7.01 (d, *J* = 8.0 Hz, 1H, ArH), 7.28–7.37 (m, 5H, ArH), 7.58 (td, *J* = 8.4, 1.0 Hz, 1H, ArH), 7.89 (d, *J* = 8.0 Hz, 1H, ArH), 9.01 (s, 1H, NH); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ<sub>C</sub> 21.4, 117.3, 123.1, 123.2, 123.8, 127.6, 130.2, 130.4, 134.0, 134.5, 140.4, 151.3; HRMS-ESI *m/z* found 289.0651 (MH<sup>+</sup>), C<sub>14</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub>S requires 289.0647 (MH<sup>+</sup>).

**2-*N*-methyl-1,2,4-benzothiadiazine-3-one 1,1-dioxide (15h):**

Using the general procedure starting from compound **13h** (50 mg, 0.208 mmol), compound **15h** was isolated as a white solid (43 mg, 0.202 mmol, 97%); *R*<sub>f</sub> (30% EtOAc/Pet) 0.53; Mp 158–160 °C; IR (KBr): 1180, 1333, 1600, 1693, 3061 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ<sub>H</sub> 3.42 (s, 3H, NCH<sub>3</sub>), 7.18 (d, *J* = 8.0 Hz, 1H, ArH), 7.29 (t, *J* = 7.8 Hz, 1H, ArH), 7.61 (t, *J* = 7.8 Hz, 1H, ArH), 7.85 (d, *J* = 7.6 Hz, 1H, ArH), 10.34 (s, 1H, NH); <sup>13</sup>C NMR (100 MHz,

CDCl<sub>3</sub>)  $\delta_C$  26.5, 117.1, 122.0, 122.8, 123.9, 134.0, 134.6, 152.0; HRMS-ESI  $m/z$  found 213.0331 (MH<sup>+</sup>), C<sub>15</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub>S requires 213.0334 (MH<sup>+</sup>).

## Reference

1. Blackburn, C.; Achab, A.; Elder, A.; Ghosh, S.; Guo, J.; Harriman, G.; Jones, M. J. *Org. Chem.* **2005**, *70*, 10206-10209. doi: 10.1021/jo051843h